HOME > About Walvax > Product

Pipeline Products

Details of Walvax's products that have entered clinical stage

No.

Key Product Candidate

Indications

Status

1

Recombinant Bivalent (Types 16/18) Human Papillomavirus (HPV) Vaccine

This vaccine is indicated for active immunization to prevent cervical cancer caused by HPV 16 and 18.

BLA under review

2

Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

This vaccine is indicated for active immunization to prevent invasive

meningococcal diseases caused by N. meningitidis serogroups A, C, Y and W135.

Clinical trial ongoing

3

Quadrivalent Influenza Vaccine

This vaccine is indicated for active immunization to prevent influenza caused by two strains of influenza A and two strains of influenza B.

Clinical trial ongoing

4

Recombinant 9-valent Human Papillomavirus

(HPV) Vaccine

This vaccine is indicated for active immunization to prevent genital warts, cervical, vulvar, vaginal, anal and other cancers caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58.

Clinical trial ongoing

5

Recombinant EV71 Virus-like Particle Vaccine

This vaccine is indicated for active immunization to prevent hand, foot and mouth disease caused by EV71.

Clinical trial ongoing

6

SARS-CoV-2 mRNA Vaccine

This vaccine is indicated for active immunization to prevent diseases caused by SARS-CoV-2

Clinical trial ongoing

*The indications of the products are subject to further amendment according to marketing approval.